Onco Wiki / Drogue

Carboplatin

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDRUG-CARBOPLATIN
TypeMédicament
Alias
ParaplatineКарбоплатин
Étatreviewed 2026-04-26 | pending_clinical_signoff
MaladiesDIS-ANAL-SCC DIS-BREAST DIS-BURKITT DIS-CERVICAL DIS-EATL DIS-ENDOMETRIAL DIS-ESOPHAGEAL DIS-GRANULOSA-CELL DIS-HNSCC DIS-HSTCL DIS-LARYNGEAL DIS-NSCLC DIS-OVARIAN DIS-PMBCL DIS-SALIVARY DIS-SCLC DIS-THYROID-ANAPLASTIC DIS-UROTHELIAL
SourcesSRC-NCCN-BCELL-2025 SRC-NCCN-ESOPHAGEAL-2025

Faits sur les drogues

CatégorieAgent alkylant de platine (de deuxième génération)
MécanismeCisplatin analog with a cyclobutane-dicarboxylate leaving group that hydrolyzes more slowly than cisplatin's chloride ligands → slower formation of activated aquated species, lower reactivity with plasma proteins, and lower nephrotoxicity / ototoxicity / neurotoxicity. The same DNA platinum-adduct biology drives cytotoxicity. Dose individualized by Calvert formula because clearance is dominated by glomerular filtration. Myelosuppression — particularly thrombocytopenia — is the dose-limiting toxicity.
Dose typiqueCalvert formula: dose (mg) = AUC × (GFR + 25). GFR cap at 125 mL/min recommended (FDA 2010) when measured by Cockcroft-Gault to avoid overdose in patients with overestimated GFR. Ovarian 1L (carbo/paclitaxel): AUC 5-6 IV q21d × 6 cycles. NSCLC (carbo/paclitaxel): AUC 6 IV q21d × 4-6 cycles. CROSS (esophageal CRT): AUC 2 IV weekly × 5 with paclitaxel 50 mg/m². ICE (lymphoma salvage): AUC 5 (max 800 mg) IV day 2. GDP, gem-carbo: AUC 4-5 IV q21d. TNBC neoadjuvant (added to AC-T or KEYNOTE-522): AUC 1.5 weekly or AUC 5 q21d with paclitaxel. Lower AUC (3-4) for elderly / frail / heavily pre-treated.
Ukraine enregistréeVrai
NSZU rembourséVrai
Ukraine vérifiée pour la dernière fois2026-04-27

Avertissements

Notes

Calvert AUC dose calculation requires GFR (Cockcroft-Gault, CKD-EPI, or measured); engine uses creatinine_clearance_ml_min finding for AUC computation. CAP at 125 mL/min per FDA 2010 to prevent overdose. Hypersensitivity prevention: gradual desensitization protocols available for re-exposure beyond cycle 6. Less hydration required than cisplatin (no mandatory pre/post hydration regimen). Platelet nadir day 14-21 — schedule q21d to allow recovery. Monitor CBC weekly for first 4 cycles.

Utilisé par

Indication

Protocole thérapeutique